+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07684300

Evaluating Molecular Microbiology-Guided vs Standard Antimicrobial Stewardship in Hospitalized Adults A Cluster-Randomized Crossover Trial

Led by Maria Espinosa Perez · Updated on 2026-07-06

250

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether combining rapid multiplex molecular microbiology results with specific clinical and laboratory criteria in an antimicrobial stewardship program improves antimicrobial use in hospitalized adults receiving high-impact antimicrobial therapy. This study compares a new stewardship strategy integrating these rapid diagnostic results against the standard antimicrobial stewardship practice currently used in the hospital. The goal is to see if this combined approach can reduce antimicrobial exposure duration, improve treatment appropriateness, and affect important clinical outcomes such as hospital readmission, ICU admission, infection recurrence, mortality, and healthcare costs. Participants receive antimicrobial management according to the stewardship strategy assigned to their hospital unit, which is randomized in a cluster crossover design. The experimental strategy involves real-time review of multiplex molecular microbiology results integrated with predefined criteria to guide antimicrobial optimization. The comparator is the standard stewardship strategy based on routine clinical and microbiological information. After one period with each strategy and a washout, hospital units switch strategies to serve as their own controls. During the trial, participants undergo molecular microbiology testing and routine clinical and laboratory assessments as part of standard hospital care when needed. Researchers track antimicrobial exposure, treatment appropriateness, safety events, and clinical outcomes including ICU admission, hospital readmission, infection recurrence, mortality, and healthcare costs. The primary outcome measured is the duration of exposure to high-impact antimicrobial therapy up to 30 days after therapy initiation. Secondary outcomes include mortality, adverse events, ICU admission, readmission, infection recurrence, and healthcare costs within specified timeframes.

CONDITIONS

Brief Title

Molecular Microbiology- Guided Antimicrobial Stewardship Versus Standard Stewardship in Hospitalized Patients

Research Team

M

María Espinosa Pérez, MD

S

Sergio Padilla Urrea, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here